Premium
Topical rapamycin for acanthosis nigricans in the Fitzpatrick IV/V adolescent population
Author(s) -
Coerdt Kathleen M.,
Todd Sarah P.,
DeKlotz Cynthia M. C.
Publication year - 2020
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.14404
Subject(s) - acanthosis nigricans , medicine , dermatology , sirolimus , population , seborrheic keratosis , obesity , insulin resistance , environmental health
Dermatologically, FGFR3 mutations can lead to acanthosis nigricans (AN), epidermal nevi, and seborrheic keratosis. A recent case report found that topical rapamycin (sirolimus) can improve FGFR3 ‐induced epidermal nevi with AN features in children, specifically with Fitzpatrick skin type (FST) I/II, and we would like to expand these findings to skin plaques with extensive AN‐like features in the FST IV/V adolescent population. An 18‐year‐old female with FST IV/V and FGFR3 ‐induced hypochondroplasia presented to our clinic with extensive AN‐like plaques. Significant improvement with lightening and thinning of the plaques was observed after applying 1% topical rapamycin cream twice daily. Topical rapamycin should be considered as a treatment option for AN, particularly in FST IV/V adolescents with FGFR3 ‐induced AN.